Shares of Moderna surged 9.5% on Tuesday to $32.75 in a notable reversal of recent bearish sentiment, buoyed by legal ...

Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years ...

Moderna’s cash flow issues are more immediate than those of its peers, so the new provision could have a greater impact on ...

The S&P 500 fell 0.1% on Tuesday, July 8, 2025, after President Trump extended the deadline for "reciprocal" tariffs and ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks to several potential product launches. A lot can happen in 10 years ...

Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years down the road, potentially benefit from a huge biotech growth story.

Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial.

A Boston-based nonprofit is among six organizations that on Monday filed a lawsuit against the U.S. Health and Human Services ...

Moderna(NASDAQ: MRNA), the next-generation healthcare company most famous for developing the Spikevax coronavirus vaccine, was an uncharacteristically popular stock.